Acadia Pharmaceuticals Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+9.4% +$24M
$284M
Cost of Revenue↑+20.3% +$4M
$26M
Gross Profit
—
R&D↓-15.9% -$16M
$85M
SG&A↑+19.6% +$26M
$156M
D&A↓-10.6% -$24K
$202K
Operating Income↓-88.7% -$136M
$17M
EBITDA↓-88.6% -$136M
$18M
Interest Expense↑+18.9% +$1M
$8M
Other Income/Expense↑+18.3% +$3M
$17M
Pretax Income↓-83.7% -$135M
$26M
Tax Provision↓-550.0% -$33M
$-27M
Net Income↑+90.3% +$130M
$274M
Gross Margin
—
Operating Margin↓-53.0pts
6.1%
Net Margin↑+41.0pts
96.3%
Effective Tax Rate↓-76.5pts
-61.0%
ETR (Continuing Operations)
-181.5%
ETR Federal Statutory
21.1%
ETR State + Local (pp)
-17.9%
Operating Lease Cost↓-0.1% -$2K
$4M
Revenue YoY Variation↓-3.0pts
9.4%
Income YoY Variation
-88.7%
Revenue QoQ Variation↓-1.8pts
1.9%
Income QoQ Variation↓-436.5pts
-51.4%